Upstream Bio, Inc.
UPB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002022626
In the last 90 days, Upstream Bio, Inc. insiders filed 0 open-market purchases and 5 sales; 148 institutions reported holding it in 13F filings for Q2 2026, worth $350.1M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $27.6K in total
- 5
- 13F holdersQ2 2026, +9 vs. previous quarter
- 148
- 13F valueReported value at the end of Q2 2026
- $350.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding UPB, Q2 2026
No superinvestor reported holding UPB at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Upstream Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)4:05 PM ET | Sep 16 | 1 day | Gray MichaelCFO and COO | SSale | −853 | $5.49 | −$4.68K | −3.0%27.9K after | |
| Sep 17, 2026 (view filing)4:05 PM ET | Sep 16 | 1 day | Ambrose AllisonGeneral Counsel | SSale | −485 | $5.49 | −$2.66K | −3.0%15.6K after | |
| Sep 17, 2026 (view filing)4:05 PM ET | Sep 16 | 1 day | Deykin AaronChief Medical Officer | SSale | −895 | $5.49 | −$4.91K | −2.7%32.3K after | |
| Sep 17, 2026 (view filing)4:05 PM ET | Sep 16 | 1 day | Sutherland Everett RandChief Executive Officer | SSale | −2.10K | $5.49 | −$11.5K | −3.0%68.7K after | |
| Sep 17, 2026 (view filing)4:05 PM ET | Sep 16 | 1 day | Houghton AdamChief Business Officer | SSale | −700 | $5.49 | −$3.84K | −3.0%22.9K after | |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Gray MichaelCFO and COO | SSale | −853 | $6.10 | −$5.20K | −2.9%28.8K after | |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Sutherland Everett RandChief Executive Officer | SSale | −2.10K | $6.10 | −$12.8K | −2.9%70.8K after | |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Houghton AdamChief Business Officer | SSale | −700 | $6.10 | −$4.27K | −2.9%23.6K after | |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Deykin AaronChief Medical Officer | SSale | −895 | $6.10 | −$5.46K | −2.6%33.2K after | |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Ambrose AllisonGeneral Counsel | SSale | −477 | $6.10 | −$2.91K | −2.9%16.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Upstream Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 8,162,897 | $56.5M | 0.00% | +61,334+0.8% | Added |
| OrbiMed Advisors LLC | 5,693,589 | $39.4M | 0.75% | 00.0% | Unchanged |
| Norges Bank | 3,768,619 | $26.1M | 0.00% | +3,768,619 | New |
| BlackRock, Inc. | 3,753,358 | $26.0M | 0.00% | +382,669+11.4% | Added |
| Decheng Capital LLC | 2,724,868 | $18.9M | 2.58% | 00.0% | Unchanged |
| Enavate Sciences GP, LLC | 2,459,703 | $17.0M | 4.93% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 1,876,734 | $13.0M | 0.00% | +3,160+0.2% | Added |
| Millennium Management LLC | 1,143,775 | $7.91M | 0.01% | +206,452+22.0% | Added |
| D. E. Shaw & Co., Inc. | 1,036,044 | $7.17M | 0.00% | +215,564+26.3% | Added |
| JPMorgan Chase & Co | 1,012,044 | $7.01M | 0.00% | +549,043+118.6% | Added |